ストックスクリーナーアプリを入手
5.12
0.99%
0.05
アフターアワーズ：
5.01
-0.11
-2.15%
前日終値:
$5.07
開ける：
$5.03
24時間の取引高:
249.62K
Relative Volume:
0.69
時価総額：
$409.74M
収益：
$351.37M
当期純損益:
$-169.52M
株価収益率:
-2.4109
EPS:
-2.1237
ネットキャッシュフロー:
$-147.86M
1週間 パフォーマンス:
-2.48%
1か月 パフォーマンス:
+8.94%
6か月 パフォーマンス:
+18.79%
1年 パフォーマンス:
+46.70%
1日の値動き範囲:
$4.99
$5.23
1週間の範囲:
$4.92
$5.55
52週間の値動き範囲:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Compare AVIR vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
5.12 | 404.94M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating - marketscreener.com
Atea Pharmaceuticals (AVIR.US) will release its earnings report after market close on August 12. - Moomoo
Atea Pharmaceuticals, Inc. (AVIR) stock price, news, quote and history - Yahoo Finance UK
Atea Pharmaceuticals Q2 2026 Earnings Call Transcript - marketbeat.com
Atea Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-08-12 - Seeking Alpha
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing - Kalkine Media
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS - marketbeat.com
Earnings call transcript: Atea beats Q2 2026 EPS view but shares fall after hours - Investing.com
ATEA PHARMACEUTICALS ($AVIR) Releases Q2 2026 Earnings - quiverquant.com
Atea Pharmaceuticals (NASDAQ: AVIR) advances HCV Phase 3 as losses widen - Stock Titan
Atea Hepatitis C Regimen Posts 93.9% Sustained Response - Stock Titan
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - Sahm
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks - webull.com
Arrowstreet Capital Limited Partnership Takes Position in Atea Pharmaceuticals, Inc. $AVIR - marketbeat.com
Atea's Aug. 12 webcast will include a business update - Stock Titan
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 - Yahoo Finance
Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Thursday - marketbeat.com
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Yahoo Finance
Atea posts late-stage trial win for hepatitis C drug (AVIR) - Seeking Alpha
Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus - marketscreener.com
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus - GlobeNewswire
AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus - European AIDS Treatment Group
Atea Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AVIR - TradingView
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Cash Flow - TradingKey
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BML Capital Management LLC Sells 431,343 Shares of Atea Pharmaceuticals, Inc. $AVIR - MarketBeat
Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy - TipRanks
Atea Pharmaceuticals (AVIR) Faces Modest Decline Near Key Support LevelIchimoku Kumo Twist - dars.gov.et
Atea Pharmaceuticals Starts Phase 1 AT-587 Trial - t.co
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating - Moomoo
Atea begins phase 1 trial of hepatitis E treatment AT-587 - Investing.com UK
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
Atea Pharmaceuticals initiates Phase 1 trial for AT-587 - scanx.trade
AVIR Q1 2026 Earnings: Narrower-than-expected Loss Drives Modest Stock GainCost Structure Review - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) Proxy filing Summary - Quartr
Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary - Quartr
Atea Pharmaceuticals (AVIR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):